Get the Stockscreener App
37.22
0.85%
-0.32
After Hours:
36.78
-0.44
-1.18%
Agios Pharmaceuticals Inc stock is traded at $37.22, with a volume of 1.10M.
It is down -0.85% in the last 24 hours and up +11.91% over the past month.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
See More
Previous Close:
$37.54
Open:
$36.9
24h Volume:
1.10M
Relative Volume:
1.80
Market Cap:
$2.16B
Revenue:
$32.87M
Net Income/Loss:
$674.31M
P/E Ratio:
3.2764
EPS:
11.36
Net Cash Flow:
$-330.11M
1W Performance:
-6.13%
1M Performance:
+11.91%
6M Performance:
+8.23%
1Y Performance:
-19.78%
1-Day Range:
$35.81
$37.94
1-Week Range:
$35.81
$40.80
52-Week Range:
$23.41
$62.58
Agios Pharmaceuticals Inc Stock (AGIO) Company Profile
Name
Agios Pharmaceuticals Inc
Sector
Industry
Phone
617-649-8600
Address
88 SIDNEY STREET, CAMBRIDGE, MA
Compare AGIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AGIO
Agios Pharmaceuticals Inc
|
37.22 | 2.17B | 32.87M | 674.31M | -330.11M | 11.36 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.87 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.46 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.24 | 44.31B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
670.33 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
301.13 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Agios Pharmaceuticals Inc Stock (AGIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-24-25 | Initiated | H.C. Wainwright | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Sep-27-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Feb-08-24 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-03-23 | Initiated | Piper Sandler | Overweight |
| Nov-17-22 | Upgrade | Goldman | Sell → Neutral |
| Jul-27-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Dec-03-21 | Initiated | BofA Securities | Buy |
| Jul-30-21 | Downgrade | Goldman | Neutral → Sell |
| Jul-01-21 | Initiated | Raymond James | Mkt Perform |
| Jun-10-21 | Initiated | H.C. Wainwright | Buy |
| Mar-01-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Mar-01-21 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Feb-26-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Oct-22-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Mar-04-20 | Initiated | Barclays | Equal Weight |
| Nov-26-19 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-23-19 | Upgrade | Guggenheim | Neutral → Buy |
| May-23-19 | Resumed | Goldman | Neutral |
| Feb-15-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Sep-25-18 | Initiated | Leerink Partners | Mkt Perform |
| May-23-18 | Initiated | Citigroup | Buy |
| Apr-11-18 | Reiterated | Credit Suisse | Outperform |
| Feb-15-18 | Reiterated | Needham | Buy |
| Feb-15-18 | Reiterated | SunTrust | Buy |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Aug-10-17 | Reiterated | Needham | Buy |
| Aug-08-17 | Reiterated | SunTrust | Buy |
| Aug-02-17 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
| Jun-26-17 | Downgrade | Janney | Buy → Neutral |
| Jan-17-17 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-24-16 | Initiated | Needham | Buy |
| Jun-13-16 | Upgrade | JP Morgan | Neutral → Overweight |
| May-18-16 | Reiterated | SunTrust | Buy |
View All
Agios Pharmaceuticals Inc Stock (AGIO) Latest News
Decoding Agios Pharmaceuticals Inc (AGIO): A Strategic SWOT Insi - GuruFocus
Agios Pharmaceuticals: Q2 Earnings Snapshot - CTPost
Agios Pharmaceuticals Q2 2025 Earnings Call Transcript - MarketBeat
Agios Pharmaceuticals: Navigating Earnings Volatility for Long-Term Growth in Rare Disease Therapeutics - AInvest
Earnings call transcript: Agios Pharm Q2 2025 earnings miss EPS, stock dips - Investing.com Canada
AGIOS PHARMACEUTICALS, INC. SEC 10-Q Report - TradingView
Agios Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
How many analysts rate Agios Pharmaceuticals Inc. as a “Buy”Top Growth Target Finder To Watch Now - jammulinksnews.com
Agios Reports Second Quarter 2025 Financial Results and Provides Business Update - The Manila Times
Agios Pharmaceuticals Reports $12.5 Million in Q2 2025 PYRUKYND® Revenues and Highlights Key Regulatory Developments - Quiver Quantitative
Agios Pharmaceuticals: Earnings Beat and Pipeline Offer Glimmers of Hope in Biotech's Volatile Landscape - AInvest
Intrahepatic Cholangiocarcinoma Market: Epidemiology, - openPR.com
Intrahepatic Cholangiocarcinoma Market: Epidemiology, Pipeline Products, Companies Working, DelveInsight | Incyte Corporation, Roche, Delcath Systems, Basilea Pharmaceutica, Agios Pharmaceuticals, Bay - Barchart.com
Live Scanner Shows Breakout on Agios Pharmaceuticals Inc.Technical Stock Breakout Predictions Signal Entry Points - metal.it
When is Agios Pharmaceuticals Inc. stock expected to show significant growthAchieve rapid wealth accumulation with smart picks - jammulinksnews.com
What is Agios Pharmaceuticals Inc. company’s growth strategyMassive wealth growth - jammulinksnews.com
What are the latest earnings results for Agios Pharmaceuticals Inc.High-yield capital appreciation - jammulinksnews.com
What are the technical indicators suggesting about Agios Pharmaceuticals Inc.Invest confidently with data-backed picks - jammulinksnews.com
What drives Agios Pharmaceuticals Inc. stock priceRecord-breaking gains - PrintWeekIndia
What risks could impact Agios Pharmaceuticals Inc. stock performanceFree Stock Market Trend Analysis - jammulinksnews.com
What analysts say about Agios Pharmaceuticals Inc. stockSuperior risk-adjusted returns - PrintWeekIndia
Is Agios Pharmaceuticals Inc. a good long term investmentTremendous financial leverage - Autocar Professional
Will Agios Pharmaceuticals Inc. stock split in the near futureJaw-dropping returns - jammulinksnews.com
When the Price of (AGIO) Talks, People Listen - news.stocktradersdaily.com
BlackRock, Inc. Reduces Stake in Agios Pharmaceuticals Inc - GuruFocus
Bank of America Securities Sticks to Their Buy Rating for Agios Pharma (AGIO) - The Globe and Mail
Agios Pharmaceuticals Inc. Stock Analysis and ForecastFree Smart Trading Workshop - jammulinksnews.com
Lobbying Update: $20,000 of AGIOS PHARMACEUTICALS lobbying was just disclosed - Quiver Quantitative
Agios Pharmaceuticals (AGIO): Analyst Maintains Buy Rating, Lowe - GuruFocus
Agios Pharmaceuticals (AGIO): BofA Adjusts Price Target Amid Rev - GuruFocus
Agios Pharmaceuticals price target lowered to $51 from $52 at BofA - TipRanks
BofA Securities Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Cuts Target Price to $51 - 富途牛牛
Agios Pharmaceuticals (AGIO) Moves 7.7% Higher: Will This Strength Last? - MSN
Agios Pharmaceuticals Inc Stock (AGIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.43%
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):